IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype

Cancer Science
Matthias ChristgenUlrich Lehmann

Abstract

Human primary breast cancers and breast cancer cell lines are classified by microarray-defined molecular subtypes, which reflect differentiation characteristics. Estrogen receptor (ER) expression is indicative of the luminal molecular subtype. We have previously established IPH-926, the first well-characterized cell line from infiltrating lobular breast cancer. IPH-926 displays an ER/PR/ErbB2 triple-negative immunophenotype, which is due to a loss of ER expression in its in vivo clonal ancestry. Loss of ER might indicate a fundamental change of cellular differentiation and it is unclear whether a luminal subtype is preserved beyond ER conversion. Using Affymetrix microarray analysis, seven different classifier gene lists (PAM305, DISC256, TN1288, PAM50, UNC1300, LAB704, INT500) and a background population of 50 common mammary carcinoma cell lines, we have now determined the molecular subtype of IPH-926. Strikingly, the IPH-926 expression profile is highly consistent with a luminal subtype. It is nearest to luminal/ER-positive breast cancer cell lines and far apart from basal breast cancer cell lines. Quantitative real-time RT-PCR confirmed enhanced expression of luminal marker genes (AGR2, CLU, CA12, EMP2, CLDN3) and low or abs...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Nov 14, 2007·International Journal of Cancer. Journal International Du Cancer·Brenda J BoersmaStefan Ambs
Apr 10, 2008·International Journal of Cancer. Journal International Du Cancer·François BertucciDaniel Birnbaum
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus P HoeflichMark R Lackner
Jul 14, 2009·Breast Cancer Research and Treatment·Antoinette HollestelleMieke Schutte
May 22, 2010·Breast Cancer Research and Treatment·Renaud SabatierFrançois Bertucci
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 3, 2011·Breast Care·Michael GnantChristoph Thomssen
Jun 28, 2011·The EMBO Journal·Jessica L L RobinsonJason S Carroll
Jul 26, 2011·Oncogene·M GuedjC Theillet
Sep 1, 2011·Nature Reviews. Clinical Oncology·Britta WeigeltJorge S Reis-Filho
Sep 3, 2011·Breast Cancer Research : BCR·Deborah L Holliday, Valerie Speirs
Sep 5, 2012·Laboratory Investigation; a Journal of Technical Methods and Pathology·Matthias ChristgenUlrich Lehmann
Sep 4, 2013·Breast Care·Nadia HarbeckMichael Gnant

❮ Previous
Next ❯

Citations

Mar 12, 2015·Breast Cancer Research : BCR·Matthias Christgen, Patrick W B Derksen
Aug 28, 2018·Statistical Methods in Medical Research·Pieter SegaertPeter J Rousseeuw
Oct 17, 2017·Laboratory Investigation; a Journal of Technical Methods and Pathology·Mieke RaapMatthias Christgen
Oct 28, 2019·Cancers·Mohammad Khusni B Ahmat AminHisakazu Ogita
Mar 29, 2020·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Yier QiuYingjie Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Caveolins & Signal Transduction

Caveolins are small proteins with a hairpin loop conformation that are located in the plasma membrane of various cell types where they bind cholesterol and interact with receptors essential for several signal transduction pathways. Here is the latest research.